The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity
Open accessAbstract
The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the immunogenicity and clinical utility of recombinant Ad5 (rAd5) vector-based vaccines for human immunodeficiency virus type 1 and other pathogens. A potential solution to this problem is to utilize rAd vaccine vectors derived from rare Ad serotypes such as Ad35 and Ad11. We have previously reported that rAd35 vectors were immunogenic in the presence of anti-Ad5 immunity, but the immunogenicity of heterologous rAd prime-boost regimens and the extent that cross-reactive anti-vector immunity may limit this approach have not been fully explored. Here we assess the immunogenicity of heterologous vaccine regimens involving rAd5, rAd35, and novel rAd11 vectors expressing simian immunodeficiency virus Gag in mice both with and without anti-Ad5 immunity. Heterologous rAd prime-boost regimens proved significantly more immunogenic than homologous regimens, as expected. Importantly, all regimens that included rAd5 were markedly suppressed by anti-Ad5 immunity. In contrast, rAd35-rAd11 and rAd11-rAd35 regimens elicited high-frequency immune responses both in the presence and in the absence of anti-Ad5 immunity, although we also detected clear cross-reactive Ad35/Ad11-specific humoral and cellular immune responses. Nevertheless, these data suggest the potential utility of heterologous rAd prime-boost vaccine regimens using vectors derived from rare human Ad serotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544
Self-citation
Cited by
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Self-citationViruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 300
Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Fausther-Bovendo, H., & Kobinger, G. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 276
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
Rojas, L. A., Condezo, G. N., Moreno, R., Fajardo, C. A., Arias-Badia, M., San Martín, C., & Alemany, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.004 · Cited by 66
Metadata
- Authors
- Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., Goudsmit, J., Havenga, M. J. E., & Barouch, D. H.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2005-08
- Volume
- 79
- Issue
- 15
- Pages
- 9694-9701
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2148123079
- Cited by
- 159
- References
- 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity. https://app.cochat.ai/papers/10.1128/jvi.79.15.9694-9701.2005
- The paper
- Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., Goudsmit, J., Havenga, M. J. E., & Barouch, D. H. (2005). Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity. Journal of Virology. https://doi.org/10.1128/jvi.79.15.9694-9701.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.